Skip to contentpdufa.bio

sutantatug envedotin (CRB-701)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

sutantatug envedotin (CRB-701) is a Corbus Pharmaceuticals Holdings, Inc. program in first-line oropharyngeal squamous cell carcinoma (OPSCC). Its next catalyst is a Readout in Q1 2027.

CRBP catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: First-line oropharyngeal squamous cell carcinoma (OPSCC). Sponsor: Corbus Pharmaceuticals Holdings, Inc. (CRBP). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027CRBP

Questions

When is sutantatug envedotin (CRB-701)'s next FDA decision or readout?

The next tracked catalyst for sutantatug envedotin (CRB-701) is a Readout in Q1 2027.

What happened at sutantatug envedotin (CRB-701)'s most recent FDA decision?

No FDA decision for sutantatug envedotin (CRB-701) is in our archive yet.

What is sutantatug envedotin (CRB-701) used for?

In our records sutantatug envedotin (CRB-701) is under review or in development for First-line oropharyngeal squamous cell carcinoma (OPSCC).

Who makes sutantatug envedotin (CRB-701)?

Corbus Pharmaceuticals Holdings, Inc. (CRBP).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.